



<input checked="" type="checkbox"/>	Trading – Interest Rate Derivatives	<input checked="" type="checkbox"/>	Back-office - Options
<input checked="" type="checkbox"/>	Trading – Equity and Index Derivatives	<input checked="" type="checkbox"/>	Technology
<input checked="" type="checkbox"/>	Back-office – Futures	<input checked="" type="checkbox"/>	Regulation

CIRCULAR
July 10, 2013

FINAL CONTRACT ADJUSTMENT
Resverlogix Corp. (RVX)
Spin-Off (Follow-Up)

THE FOLLOWING INFORMATION IS PREPARED FOR THE CONVENIENCE OF CANADIAN DERIVATIVES CLEARING CORPORATION (CDCC) CLEARING MEMBERS AND BOURSE DE MONTRÉAL INC. (THE BOURSE) APPROVED PARTICIPANTS. THIS DOCUMENT IS AN UNOFFICIAL SUMMARY OF CERTAIN TERMS OF THE AFOREMENTIONED ADJUSTMENT. CDCC AND THE BOURSE ACCEPT NO RESPONSIBILITY FOR THE ACCURACY OR COMPLETENESS OF THE SUMMARY. CDCC MEMBERS AND BOURSE APPROVED PARTICIPANTS MUST ENSURE THEY HAVE REVIEWED THE DOCUMENTATION PUBLISHED BY THE ISSUERS INVOLVED IN THIS CORPORATE ACTION.

The Bourse and CDCC wish to inform you that, further to the announcement of a plan of arrangement for a spin-off of Resverlogix Corp. (« Resverlogix ») as referred to in Circular No. 106-13 and Notice to Members No. 149-13 published on June 3, 2013, Resverlogix has released its estimation of the proportionate allocation of the adjusted cost base of the Resverlogix common share before the spin-off as: one Resverlogix new common share for 90.9% and one Zenith Epigenetics Corp. (« Zenith ») common share for 9.1%, based on their respective fair market values immediately after the spin-off.

The Adjustments Committee referred to in Rule A-9 of the CDCC Rules met on June 28, 2013 and determined, based on Resverlogix's estimation, that the value of Resverlogix common share before the spin-off should be set at the price as at the close of the record date, May 31, 2013, i.e. CAD\$3.67. The Adjustments Committee determined accordingly that the new deliverable per RVX1 contract would be as follow:

- **NEW DELIVERABLE PER CONTRACT:** **100 common shares of Resverlogix (Symbol: RVX) and a cash portion equivalent to 100 units of Zenith which is equal to CAD\$33.40 (9.1% of the fair market value of Resverlogix before the spin-off).**

The cash amount of the deliverable remains permanently fixed as the option deliverable and will not vary.

PLEASE ENSURE THAT ALL CLIENTS WHO HAVE EITHER LONG OR SHORT POSITIONS IN THIS OPTIONS CLASS ARE ADVISED OF THIS NOTICE.

For further information, please contact Louise Leclair, Trading Systems Analyst Market Operations, Bourse de Montréal Inc. at (514) 871-3526. Clearing members may contact the CDCC Member Services

Brian Gelfand
Vice-President, Institutional Relations and Market Operations

Circular no.: 127-2013